Janux Therapeutics Inc

NASDAQ JANX

Data sourced from

and

Download Data

Janux Therapeutics Inc Cash and Short-Term Investments for the Trailing 12 Months (TTM) ending March 31, 2024: USD 651.76 M

Janux Therapeutics Inc Cash and Short-Term Investments is USD 651.76 M for the Trailing 12 Months (TTM) ending March 31, 2024, a 105.68% change year over year. Cash and Short-Term Investments is the sum of cash and short-term investments, representing the company's liquid assets.

Janux Therapeutics Inc Cash and Short-Term Investments for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 316.88 M, a -12.27% change year over year.
Janux Therapeutics Inc Cash and Short-Term Investments for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 361.20 M, a 410.39% change year over year.
Janux Therapeutics Inc Cash and Short-Term Investments for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 70.77 M.

NASDAQ: JANX

Janux Therapeutics Inc

CEO	Dr. David Alan Campbell Ph.D.
IPO Date	June 11, 2021
Location	United States
Headquarters	11099 North Torrey Pines Road, La Jolla, CA, United States, 92037
Employees	68
Sector	Healthcare
Industry	Biotechnology

Description

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Key trends